Priya Cherian Huskins - Sep 29, 2023 Form 4 Insider Report for Envoy Medical, Inc. (ANZU)

Role
Director
Signature
/s/ Andrew P. Campbell as attorney-in-fact for Priya Cherian Huskins
Stock symbol
ANZU
Transactions as of
Sep 29, 2023
Transactions value $
$0
Form type
4
Date filed
10/3/2023, 09:52 PM
Previous filing
May 25, 2023
Next filing
May 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANZU Class A Common Stock, par value $0.0001 per share Conversion of derivative security $0 +25K $0.00 25K Sep 29, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANZU Class B Common Stock, par value $0.0001 per share Conversion of derivative security $0 -25K -100% $0.00* 0 Sep 29, 2023 Class A Common Stock, par value $0.0001 per share 25K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Priya Cherian Huskins is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.